Galapagos NV PG) has the transferred databases for predictive drug discovery to the EMBL's European Bioinformatics Institute (EMBL-EBI).
The data, which were offered previously through Galapagos' BioFocus DPI service division, will become publicly available on-line to drug discovery researchers worldwide through the EMBL-EBI under license from Galapagos.
Galapagos will receive £1.4 million (EUR 1.8 million) in cash. To obtain the rights to the databases, the EMBL-EBI has received funding from the Wellcome Trust, the largest charity in the United Kingdom. The EMBL-EBI will provide access to these data under a grant from the Trust.
This agreement involves a suite of databases for selection of the best biological targets for discovery of novel drugs, based on the most appropriate drug-like chemistry starting points. Major databases included under the agreement are: DrugStore(TM) (database of known drugs), StARLITe(TM) (database of known compounds and their effects), Strudle(TM) (binding site drugability), and Kinase SARfari(TM) and GPCR SARfari(TM) (informatics systems for the most widely used target classes in drug discovery).
The StarDrop(TM) software platform to guide decisions and focus resources on optimal chemical compounds in drug discovery is not part of the transaction and will continue to be offered by BioFocus DPI.